Potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Inhibits recombinant BTK with an IC50
value of 2.5 μ
M and has no activity on other protein kinases ( including JAK1, JAK3, HCK, EGFR kinase and insulin receptor kinase) at concentrations of up to 278 μ
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex.
Vassilev et al.
Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide].
Mahajan et al.
Interaction of Bruton's tyrosine kinase and protein kinase Cθ in platelets.
Crosby and Pool
The citations listed below are publications that use Tocris products. Selected citations for LFM-A13 include:
Showing Results 1 - 1 of 1